Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single suprachoroidal injection of AL-001 in wet AMD (Phase II, randomized active-controlled, China)
CTR20250564Phase 2Active
- Sponsor
- Anlong Bio
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of AL001 in exudative macular degeneration, sponsored by Anlong Bio. Started Feb 2025; status: active.
02
Drugs
AL001
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20250564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250564.